dose range comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
In cell biology, cell fractionation is the process used to separate cellular components while preserving individual functions of each component. This is a method that was originally used to demonstrate the cellular location of various biochemical processes. Other uses of subcellular fractionation is to provide an enriched source of a protein for further purification, and facilitate the diagnosis of various disease states.
Perfluoroalkyl carboxylic acids (PFCAs), such as trifluoroacetic acid (TFA) Perfluorosulfonic acids (PFSAs), such as perfluorooctanesulfonic acid (PFOS) Precursors to PFCAs, such as fluorotelomers, including as fluorotelomer alcohols (FTOHs) Precursors to PFSAs, such as perfluorobutane sulfonamide (H-FBSA), perfluorooctanesulfonamide (PFOSA), perfluorobutanesulfonyl fluoride (PFOSB) or perfluorooctanesulfonyl fluoride (PFOSF) Fluoropolymers such as polytetrafluoroethylene (PTFE, aka Teflon)
=== 16 April === The SBU claimed to have destroyed a Russian Nebo-U radar system in Bryansk Oblast using drones. Russian-installed officials in Zaporizhzhia Oblast said that Anton Yakimenko, a member of the district council of occupied Yakymivka, was lightly injured in a bomb attack as part of an assassination attempt. Ukraine announced that it was testing an "unmanned submarine" that can be fitted with a warhead, stealth features and sensors, carry up to 10 divers, carry six torpedoes or missiles and has an endurance of 54 hours/1000 km, with a speed of up to 50 km/h underwater. Zelenskyy signed the revised mobilization bill into law. Denmark announced a new military aid package for Ukraine valued at 2.2 billion kroner ($313 million) that is partly aimed at weapons production in the Czech Republic.
Sources: en.wikipedia.org
== Research == Wadden’s research has focused on the behavioral and medical management of obesity. His early work on very low-calorie diets (VLCDs) included the first long-term trial of high-protein VLCDs, showing short-term efficacy but frequent weight regain, which underscored the need for long-term maintenance strategies. In the 1990s, he helped establish methods for evaluating commercial weight-loss programs, contributing to federal consumer-protection efforts. Beginning in the late 1990s, Wadden’s trials demonstrated that combining weight-loss medications with intensive lifestyle intervention (ILI) produced greater weight reduction than either approach alone, shaping clinical guidelines and drug trial designs. He also played a central role in research that supports the Centers for Medicare and Medicaid Services reimbursement of intensive behavioral therapy (IBT) for obesity. His studies showed that brief, protocol-driven IBT sessions delivered in primary care produced clinically meaningful weight loss. As a principal investigator on the NIH-funded Look AHEAD trial, Wadden helped show that ILI improved cardiometabolic risk factors, physical function, quality of life, and health-care costs in patients with type 2 diabetes, despite not reducing cardiovascular events. More recently, he has reported on glucagon-like peptide-1 (GLP-1) medications such as semaglutide and tirzepatide, which produce substantial weight loss and health benefits.
Types include astrocytes, oligodendrocytes, microglia, and Schwann cells. Glia limitans A thin layer of astrocytic endfeet beneath the pia mater that forms part of the barrier separating the brain parenchyma from the cerebrospinal fluid. Glial scar A dense accumulation of glial cells, particularly astrocytes, that forms after central nervous system injury. It helps contain damage but can also inhibit axonal regeneration. Glioblastoma A highly aggressive and malignant brain tumor arising from glial cells. It is the most common primary brain cancer in adults and often has a poor prognosis. Glucocorticoid A class of steroid hormones released by the adrenal cortex in response to stress. They influence metabolism and have significant effects on memory and the hippocampus. Glutamate The main excitatory neurotransmitter in the brain. It is essential for learning, memory, and synaptic plasticity, but excessive levels can cause excitotoxicity. Glutamatergic Describes neurons or synapses that use glutamate as a neurotransmitter. These are the majority of excitatory synapses in the brain. Glycine An inhibitory neurotransmitter found primarily in the spinal cord and brainstem. It acts via glycine receptors and contributes to motor control and reflexes. Golgi cell A type of inhibitory interneuron in the cerebellum that regulates input from mossy fibers to granule cells via GABA release. Golgi stain A silver staining method that randomly labels a small subset of neurons in their entirety, allowing detailed study of neuronal morphology.
In the north, either a single new state consisting of Schleswig-Holstein, Hamburg, Bremen and Lower Saxony should be created (solution A) or two new states, one in the northeast consisting of Schleswig-Holstein, Hamburg and the northern part of Lower Saxony (from Cuxhaven to Lüchow-Dannenberg) and one in the northwest consisting of Bremen and the rest of Lower Saxony (solution B). In the center and southwest, one alternative was that Rhineland-Palatinate (with the exception of the Germersheim district but including the Rhine-Neckar region) should be merged with Hesse and the Saarland (solution C), the district of Germersheim would then become part of Baden-Württemberg. The other alternative was that the Palatinate (including the region of Worms) could be merged with the Saarland and Baden-Württemberg, and the rest of Rhineland-Palatinate would then merge with Hesse (solution D). Both alternatives could be combined (AC, BC, AD, BD). At the same time, the commission developed criteria for classifying the terms of Article 29 Paragraph 1. The capacity to perform functions effectively was considered most important, whereas regional, historical, and cultural ties were considered as hardly verifiable. To fulfill administrative duties adequately, a population of at least five million per state was considered as necessary. After a relatively brief discussion and mostly negative responses from the affected states, the proposals were shelved. Public interest was limited or nonexistent. The referendum in Baden was held on 7 June 1970.
Kwashiorkor ( KWOSH-ee-OR-kor, -kər) is a form of severe protein malnutrition characterized by edema and an enlarged liver with fatty infiltrates. It is thought to be caused by sufficient calorie intake, but with insufficient protein consumption (or lack of good quality protein). It is different from marasmus, which is malnutrition of all sources of energy including protein. Recent studies have found that a lack of antioxidant micronutrients such as β-carotene, lycopene, other carotenoids, and vitamin C as well as the presence of aflatoxins may play a role in the development of the disease. However, the exact cause of kwashiorkor is still unknown. Inadequate food supply is correlated with kwashiorkor; occurrences in high-income countries are rare. It occurs amongst weaning children to ages of about five years old. Conditions analogous to kwashiorkor were well documented around the world throughout history. The disease's first formal description was published by Jamaican pediatrician Cicely Williams in 1933. She was the first to research kwashiorkor, and to suggest that it might be a protein deficiency to differentiate it from other dietary deficiencies. The name, introduced by Williams in 1935, was derived from the Ga language of coastal Ghana, translated as "the sickness the baby gets when the new baby comes" or "the disease of the deposed child", and reflecting the development of the condition in an older child who has been weaned from the breast when a younger sibling comes. Breast milk contains amino acids vital to a child's growth.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.